BioPharm Insight Releases its Catalyst Monitor for February 2013

Share Article

Celgene, Roche/Immunogen and Dynavax are all likely to see FDA approvals

Major market-moving events noted in BioPharm Insight’s February Catalyst Monitor include potential US therapeutic approvals for Celgene, Roche/ImmunoGen and Dynavax Technologies.

After notification from the US Food and Drug Administration (FDA) that the Oncologic Drugs Advisory Committee meeting scheduled for 8 November 2012 was canceled, experts agreed Celgene’s pomalidomide is still on track to be given the go-ahead. The fact that the FDA canceled the meeting as opposed to postponing it as they frequently do suggests a decision has been made. Experts interviewed noted the only concern with pomalidomide could be the risk of second primary malignancy but that the drug has a similar side-effect profile to Celgene’s approved multiple myeloma drug, Revlimid (lenalidomide), and should thus be green-lighted without any problem.

In November, Roche/ImmunoGen announced the FDA had accepted their Biologics License Application and granted Priority Review for T-DM1 as a treatment for unresectable locally advanced or metastatic HER2+ breast cancer patients who have received prior treatment with Herceptin (trastuzumab) and a taxane chemotherapy. Oncologists interviewed by this news service expected to see limited off-label use in the first-line setting after second-line approval since insurance carriers are likely to push back.

Lastly, with a Prescription Drug User Fee Act date of 24 February 2013, Dynavax’s Heplisav may see FDA approval in hepatitis B subgroups but fall short in the broader population of patients 18-70 years old. Experts are in disagreement on whether safety issues in the larger patient group warrant pre- or postmarketing studies.

Read the full 14 page report, start your free trial today.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides clients with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit

About Infinata, Inc.
Featuring a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Holly Burke
Email >
Follow us on
Visit website